TipRanks
Clinuvel Pharmaceuticals Limited (DE:UR9)
FRANKFURT:UR9
Germany Market
UR9
Clinuvel Pharmaceuticals
RESEARCH TOOLSreports

Clinuvel Pharmaceuticals (UR9) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

UR9 Analyst Ratings

Moderate Buy
5Ratings
Moderate Buy
2 Buy
3 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Clinuvel
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

UR9 Stock 12 Month Forecast

Average Price Target

€10.51
▲(98.24% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Clinuvel Pharmaceuticals in the last 3 months. The average price target is €10.51 with a high forecast of €24.36 and a low forecast of €5.90. The average price target represents a 98.24% change from the last price of €5.30.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","25":"€25","9.25":"€9.25","14.5":"€14.5","19.75":"€19.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24.360105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€24.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.5064575,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€10.51</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.900972,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€5.90</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,9.25,14.5,19.75,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.02,6.507700384615385,7.995400769230769,9.483101153846153,10.970801538461538,12.458501923076923,13.946202307692307,15.433902692307692,16.921603076923077,18.409303461538464,19.897003846153847,21.38470423076923,22.872404615384614,{"y":24.360105,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.02,5.442035192307692,5.864070384615384,6.2861055769230765,6.708140769230769,7.130175961538461,7.552211153846153,7.974246346153846,8.396281538461539,8.81831673076923,9.240351923076922,9.662387115384615,10.084422307692307,{"y":10.5064575,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.02,5.087767076923076,5.155534153846154,5.223301230769231,5.291068307692307,5.358835384615385,5.426602461538462,5.494369538461538,5.562136615384615,5.629903692307693,5.697670769230769,5.765437846153846,5.833204923076924,{"y":5.900972,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.995,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.571,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.332,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.71,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.959,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.024,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.024,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.666,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.597,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.656,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.915,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.467,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.02,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€24.36Average Price Target€10.51Lowest Price Target€5.90
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgans Analyst forecast on DE:UR9
Iain Wilkie
Morgans
Morgans
€6.2
Hold
16.95%
Upside
Downgraded
08/31/26
Clinuvel Pharmaceuticals (CLVLF) was downgraded to a Hold Rating at Morgans
Jefferies Analyst forecast on DE:UR9
David Stanton
Jefferies
Jefferies
€25.29→€24.36
Buy
359.62%
Upside
Reiterated
08/30/26
Analysts' Top Healthcare Picks: Clinuvel Pharmaceuticals (CLVLF), AgomAb Therapeutics NV ADR (AGMB)
MA Financial Group Analyst forecast on DE:UR9
Sarah Mann
MA Financial Group
MA Financial Group
€8.94
Buy
68.76%
Upside
Reiterated
08/30/26
MA Financial Group Sticks to Their Buy Rating for Clinuvel Pharmaceuticals (CLVLF)
Canaccord Genuity Analyst forecast on DE:UR9
Madeleine Williams
Canaccord Genuity
Canaccord Genuity
€5.9
Hold
11.34%
Upside
Downgraded
08/27/26
Clinuvel Pharmaceuticals (CLVLF) was downgraded to a Hold Rating at Canaccord Genuity
Bell Potter Analyst forecast on DE:UR9
Thomas Wakim
Bell Potter
Bell Potter
€7.13
Hold
34.50%
Upside
Downgraded
08/27/26
Analysts Offer Insights on Healthcare Companies: Polynovo (Other OTC: CALZF), Clinuvel Pharmaceuticals (Other OTC: CLVLF) and Impedimed Limited (Other OTC: IPDQF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgans Analyst forecast on DE:UR9
Iain Wilkie
Morgans
Morgans
€6.2
Hold
16.95%
Upside
Downgraded
08/31/26
Clinuvel Pharmaceuticals (CLVLF) was downgraded to a Hold Rating at Morgans
Jefferies Analyst forecast on DE:UR9
David Stanton
Jefferies
Jefferies
€25.29→€24.36
Buy
359.62%
Upside
Reiterated
08/30/26
Analysts' Top Healthcare Picks: Clinuvel Pharmaceuticals (CLVLF), AgomAb Therapeutics NV ADR (AGMB)
MA Financial Group Analyst forecast on DE:UR9
Sarah Mann
MA Financial Group
MA Financial Group
€8.94
Buy
68.76%
Upside
Reiterated
08/30/26
MA Financial Group Sticks to Their Buy Rating for Clinuvel Pharmaceuticals (CLVLF)
Canaccord Genuity Analyst forecast on DE:UR9
Madeleine Williams
Canaccord Genuity
Canaccord Genuity
€5.9
Hold
11.34%
Upside
Downgraded
08/27/26
Clinuvel Pharmaceuticals (CLVLF) was downgraded to a Hold Rating at Canaccord Genuity
Bell Potter Analyst forecast on DE:UR9
Thomas Wakim
Bell Potter
Bell Potter
€7.13
Hold
34.50%
Upside
Downgraded
08/27/26
Analysts Offer Insights on Healthcare Companies: Polynovo (Other OTC: CALZF), Clinuvel Pharmaceuticals (Other OTC: CLVLF) and Impedimed Limited (Other OTC: IPDQF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
LFMDLifeMD
ORKAOruka Therapeutics
ACHVAchieve Life Sciences
PLSEPulse Biosciences
PMNProMIS Neurosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Clinuvel Pharmaceuticals

3 Months
David StantonJefferies
Success Rate
3/11 ratings generated profit
27%
Average Return
-7.41%
Copying David Stanton's trades and holding each position for 3 Months would result in 27.27% of your transactions generating a profit, with an average return of -7.41% per trade.
1 Year
David StantonJefferies
Success Rate
1/11 ratings generated profit
9%
Average Return
-15.55%
Copying David Stanton's trades and holding each position for 1 Year would result in 9.09% of your transactions generating a profit, with an average return of -15.55% per trade.
2 Years
David StantonJefferies
Success Rate
0/11 ratings generated profit
0%
Average Return
-21.40%
Copying David Stanton's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -21.40% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

UR9 Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
3
2
2
2
2
Buy
0
0
0
1
1
Hold
0
0
0
3
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
2
2
6
6
In the current month, UR9 has received 3 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. UR9 average Analyst price target in the past 3 months is 10.51.
Each month's total comprises the sum of three months' worth of ratings.

UR9 Financial Forecast

UR9 Earnings Forecast

Next quarter’s earnings estimate for UR9 is €0.15 with a range of €0.12 to €0.22. The previous quarter’s EPS was €0.29. UR9 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year UR9 has Performed in-line its overall industry.
Next quarter’s earnings estimate for UR9 is €0.15 with a range of €0.12 to €0.22. The previous quarter’s EPS was €0.29. UR9 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year UR9 has Performed in-line its overall industry.

UR9 Sales Forecast

Next quarter’s sales forecast for UR9 is €22.36M with a range of €21.91M to €22.77M. The previous quarter’s sales results were €35.24M. UR9 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year UR9 has Performed in-line its overall industry.
Next quarter’s sales forecast for UR9 is €22.36M with a range of €21.91M to €22.77M. The previous quarter’s sales results were €35.24M. UR9 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year UR9 has Performed in-line its overall industry.

UR9 Stock Forecast FAQ

What is DE:UR9’s average 12-month price target, according to analysts?
Based on analyst ratings, Clinuvel Pharmaceuticals Limited’s 12-month average price target is 10.51.
    What is DE:UR9’s upside potential, based on the analysts’ average price target?
    Clinuvel Pharmaceuticals Limited has 98.24% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Clinuvel Pharmaceuticals Limited a Buy, Sell or Hold?
          Clinuvel Pharmaceuticals Limited has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Clinuvel Pharmaceuticals Limited’s share price target?
            The average share price target for Clinuvel Pharmaceuticals Limited is 10.51. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €24.36 ,and the lowest forecast is €5.90. The average share price target represents 98.24% Increase from the current price of €5.3.
              What do analysts say about Clinuvel Pharmaceuticals Limited?
              Clinuvel Pharmaceuticals Limited’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of Clinuvel Pharmaceuticals Limited?
                To buy shares of DE:UR9, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.